MA37951A1 - Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium - Google Patents
Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésiumInfo
- Publication number
- MA37951A1 MA37951A1 MA37951A MA37951A MA37951A1 MA 37951 A1 MA37951 A1 MA 37951A1 MA 37951 A MA37951 A MA 37951A MA 37951 A MA37951 A MA 37951A MA 37951 A1 MA37951 A1 MA 37951A1
- Authority
- MA
- Morocco
- Prior art keywords
- irbesartan
- atorvastatin
- magnesium carbonate
- tablet formulation
- composite tablet
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 title abstract 2
- 229960005370 atorvastatin Drugs 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title abstract 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002198 irbesartan Drugs 0.000 title abstract 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 title abstract 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 title abstract 2
- 239000001095 magnesium carbonate Substances 0.000 title abstract 2
- 239000007916 tablet composition Substances 0.000 title abstract 2
- 229960001708 magnesium carbonate Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une formulation de comprimé composite bicouche comprenant (a) une première couche comportant de l'irbesartane ou son sel pharmaceutiquement acceptable, et (b) une seconde couche comportant de l'atorvastatine ou son sel pharmaceutiquement acceptable et du carbonate de magnésium (m
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120096477A KR20140028971A (ko) | 2012-08-31 | 2012-08-31 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| PCT/KR2013/007838 WO2014035188A1 (fr) | 2012-08-31 | 2013-08-30 | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37951A1 true MA37951A1 (fr) | 2018-06-29 |
| MA37951B2 MA37951B2 (fr) | 2019-12-31 |
Family
ID=50183917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37951A MA37951B2 (fr) | 2012-08-31 | 2013-08-30 | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150209290A1 (fr) |
| EP (1) | EP2890368A4 (fr) |
| JP (1) | JP6363079B2 (fr) |
| KR (1) | KR20140028971A (fr) |
| CN (1) | CN104602677A (fr) |
| AR (1) | AR092386A1 (fr) |
| AU (1) | AU2013309686B2 (fr) |
| BR (1) | BR112015004471A8 (fr) |
| CA (1) | CA2882735A1 (fr) |
| CL (1) | CL2015000402A1 (fr) |
| CR (1) | CR20150115A (fr) |
| DO (1) | DOP2015000040A (fr) |
| EA (1) | EA030306B1 (fr) |
| EC (1) | ECSP15010600A (fr) |
| GT (1) | GT201500043A (fr) |
| IL (1) | IL237424A0 (fr) |
| IN (1) | IN2015DN01463A (fr) |
| MA (1) | MA37951B2 (fr) |
| MX (1) | MX354800B (fr) |
| MY (1) | MY175897A (fr) |
| NI (1) | NI201500027A (fr) |
| NZ (1) | NZ706472A (fr) |
| PE (1) | PE20150935A1 (fr) |
| PH (1) | PH12015500394A1 (fr) |
| RU (1) | RU2015111546A (fr) |
| SG (1) | SG11201500584YA (fr) |
| TW (1) | TWI651101B (fr) |
| UA (1) | UA115995C2 (fr) |
| UY (1) | UY35001A (fr) |
| WO (1) | WO2014035188A1 (fr) |
| ZA (1) | ZA201502156B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6981088B2 (ja) * | 2017-01-27 | 2021-12-15 | ニプロ株式会社 | 経口固形製剤 |
| WO2019018155A1 (fr) * | 2017-07-17 | 2019-01-24 | Eli Lilly And Company | Compositions pharmaceutiques |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270317A (en) | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| US20030114497A1 (en) | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| TW200812619A (en) * | 2006-04-06 | 2008-03-16 | Schering Corp | TRA combination therapies |
| KR20090114325A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 약제학적 제제 |
| JP5534004B2 (ja) * | 2010-03-29 | 2014-06-25 | アステラス製薬株式会社 | 口腔内崩壊錠 |
| KR101248804B1 (ko) | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
-
2012
- 2012-08-31 KR KR1020120096477A patent/KR20140028971A/ko active Search and Examination
-
2013
- 2013-08-29 AR ARP130103083A patent/AR092386A1/es unknown
- 2013-08-30 EA EA201590469A patent/EA030306B1/ru not_active IP Right Cessation
- 2013-08-30 JP JP2015529683A patent/JP6363079B2/ja not_active Expired - Fee Related
- 2013-08-30 MA MA37951A patent/MA37951B2/fr unknown
- 2013-08-30 CN CN201380045377.2A patent/CN104602677A/zh active Pending
- 2013-08-30 BR BR112015004471A patent/BR112015004471A8/pt not_active IP Right Cessation
- 2013-08-30 TW TW102131243A patent/TWI651101B/zh not_active IP Right Cessation
- 2013-08-30 MX MX2015002526A patent/MX354800B/es active IP Right Grant
- 2013-08-30 US US14/421,467 patent/US20150209290A1/en not_active Abandoned
- 2013-08-30 IN IN1463DEN2015 patent/IN2015DN01463A/en unknown
- 2013-08-30 NZ NZ706472A patent/NZ706472A/en not_active IP Right Cessation
- 2013-08-30 SG SG11201500584YA patent/SG11201500584YA/en unknown
- 2013-08-30 RU RU2015111546A patent/RU2015111546A/ru unknown
- 2013-08-30 EP EP13833700.1A patent/EP2890368A4/fr not_active Withdrawn
- 2013-08-30 MY MYPI2015700489A patent/MY175897A/en unknown
- 2013-08-30 UY UY0001035001A patent/UY35001A/es not_active Application Discontinuation
- 2013-08-30 UA UAA201502939A patent/UA115995C2/uk unknown
- 2013-08-30 WO PCT/KR2013/007838 patent/WO2014035188A1/fr active Application Filing
- 2013-08-30 AU AU2013309686A patent/AU2013309686B2/en not_active Ceased
- 2013-08-30 PE PE2015000220A patent/PE20150935A1/es not_active Application Discontinuation
- 2013-08-30 CA CA2882735A patent/CA2882735A1/fr not_active Abandoned
-
2015
- 2015-02-19 CL CL2015000402A patent/CL2015000402A1/es unknown
- 2015-02-24 PH PH12015500394A patent/PH12015500394A1/en unknown
- 2015-02-25 IL IL237424A patent/IL237424A0/en unknown
- 2015-02-26 GT GT201500043A patent/GT201500043A/es unknown
- 2015-02-26 DO DO2015000040A patent/DOP2015000040A/es unknown
- 2015-02-27 NI NI201500027A patent/NI201500027A/es unknown
- 2015-03-05 CR CR20150115A patent/CR20150115A/es unknown
- 2015-03-20 EC ECIEPI201510600A patent/ECSP15010600A/es unknown
- 2015-03-30 ZA ZA2015/02156A patent/ZA201502156B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291613A (en) | Anticoagulant monoclonal antibodies (anti–factor xii/fxiia), method for their preparation, pharmaceutical compound containing them and medical uses | |
| EP3378850B8 (fr) | Procédés pour la préparation de (s)-l-(3-éthoxy-4-méthoxyphényl)-2- méthanesulfonyléthylamine | |
| EP2599471A4 (fr) | Dispositif de coupe de comprimés | |
| FR2981187B1 (fr) | Tablette de communication pour l'enseignement | |
| GB201017345D0 (en) | Receptor antagonists | |
| FR2962303B1 (fr) | Casque de protection amélioré pour la pratique des sports | |
| EP3020717A4 (fr) | Antagoniste des récepteurs p2x4 | |
| EP2938096A4 (fr) | Structure transmettant un son, film transmettant un son et boîtier résistant à l'eau | |
| IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
| UA107967C2 (en) | Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan | |
| EP2641077A4 (fr) | Intégration optofluidique planar hybride | |
| EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
| FR3003747B1 (fr) | Systeme pour abouter deux vaisseaux sanguins. | |
| EE05653B1 (et) | Ssinikkomposiitelektrood elektrilise kaksikkihi kondensaatorile | |
| EA201390335A1 (ru) | Введение лоркасерина индивидуумам с почечной недостаточностью | |
| JO3225B1 (ar) | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 | |
| EP3008243A4 (fr) | Structures de serviettes feuilletées comportant des macro-algues | |
| JP2011173937A5 (fr) | ||
| IL232061A (en) | The heterocyclic compound in the bicycle, a pharmaceutical product containing it and its use | |
| MA37951A1 (fr) | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium | |
| WO2011097527A3 (fr) | Immunoprotection de fractions thérapeutiques avec des régions fc améliorées | |
| WO2011136489A3 (fr) | Capteur d'image pour capsule endoscopique permettant un fonctionnement à deux modes | |
| TR201104239A2 (tr) | 3B görüntülere yönelik 3B çerçeve senkronizasyonu.@ | |
| WO2012111961A3 (fr) | Comprimé à libération prolongée, administré par voie orale, contenant de la tianeptine ou un sel pharmaceutiquement acceptable de celle-ci | |
| FR2969131B1 (fr) | Systeme de securite pour conteneur semi-enterre. |